MYCOF News and Press, New Age Brands From 02/03/22

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, e...

VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today...

Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institu...

Mydecine Innovations (OTCPK:MYCOF) submitted a pre-investigational new drug (IND) briefing package to the U.S. Food and Drug Administration (FDA) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program. The phase 2/3 study will assess the safety and e...

DENVER, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, tod...

During a National Institutes for Health workshop on the use of psychedelic drugs as therapeutics, Dr. Nora Volkow, director of the National Institute on Drug Abuse (“NIDA”), suggested that the psychedelics reform movement was here to stay. Volkow stated that individuals would...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, o...

A new study has found that adults who were mistreated or abused as children and suffer from PTSD as a result of this may benefit from cognitive behavioral therapy . The study was carried out by a team of 15 therapists led by Danielle Oprel, a clinical psychologist, and Chris Hoeber, a PhD c...

Recently, Pennsylvania state Reps Jennifer O’Mara and Tracy Pennycuick introduced the Public Health Benefits of Psilocybin Act to the House. The measure, dubbed House Bill 1959 , will allow studies to be conducted on the use of psilocybin as a treatment of various mental health condi...

Researchers at the University of Virginia are conducting new research that will assist in identifying and helping individuals who are struggling with addiction, through the institution’s Center for Leading Edge Addiction Research (“CLEAR”), which develops addiction t...